<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39204436</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Formulation of Polymeric Nanoparticles Loading Baricitinib as a Topical Approach in Ocular Application.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1092</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16081092</ELocationID><Abstract><AbstractText>Topical ocular drug delivery faces several challenges due to the eye's unique anatomy and physiology. Physiological barriers, tear turnover, and blinking hinder the penetration of drugs through the ocular mucosa. In this context, nanoparticles offer several advantages over traditional eye drops. Notably, they can improve drug solubility and bioavailability, allow for controlled and sustained drug release, and can be designed to specifically target ocular tissues, thus minimizing systemic exposure. This study successfully designed and optimized PLGA and PCL nanoparticles for delivering baricitinib (BTB) to the eye using a factorial design, specifically a three-factor at five-levels central rotatable composite 2<sup>3+</sup> star design. The nanoparticles were small in size so that they would not cause discomfort when applied to the eye. They exhibited low polydispersity, had a negative surface charge, and showed high entrapment efficiency in most of the optimized formulations. The Challenge Test assessed the microbiological safety of the nanoparticle formulations. An ex vivo permeation study through porcine cornea demonstrated that the nanoparticles enhanced the permeability coefficient of the drug more than 15-fold compared to a plain solution, resulting in drug retention in the tissue and providing a depot effect. Finally, the in vitro ocular tolerance studies showed no signs of irritancy, which was further confirmed by HET-CAM testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beirampour</LastName><ForeName>Negar</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9992-5406</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustos-Salgado</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9453-9191</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrós</LastName><ForeName>Núria</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2571-2066</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi-Meyabadi</LastName><ForeName>Roya</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4799-6362</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domènech</LastName><ForeName>Òscar</ForeName><Initials>Ò</Initials><Identifier Source="ORCID">0000-0002-7281-8915</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suñer-Carbó</LastName><ForeName>Joaquim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9238-187X</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez-Lagunas</LastName><ForeName>María José</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-7870-8250</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapravelou</LastName><ForeName>Garyfallia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8414-9723</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Institute of Nutrition and Food Technology (INyTA), Biomedical Research Center (CIBM), Universidad de Granada, 18100 Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montes</LastName><ForeName>María Jesús</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0771-8301</Identifier><AffiliationInfo><Affiliation>Department de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calpena</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4989-4821</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallandrich</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9316-8459</Identifier><AffiliationInfo><Affiliation>Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 29-31, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Nanociència i Nanotecnologia, Universitat de Barcelona (UB), 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">baricitinib</Keyword><Keyword MajorTopicYN="N">ocular delivery</Keyword><Keyword MajorTopicYN="N">ocular tolerance</Keyword><Keyword MajorTopicYN="N">poly(lactic-co-glycolic acid) nanoparticles</Keyword><Keyword MajorTopicYN="N">poly(ε-caprolactone) nanoparticles</Keyword><Keyword MajorTopicYN="N">transcorneal permeation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39204436</ArticleId><ArticleId IdType="pmc">PMC11360485</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16081092</ArticleId><ArticleId IdType="pii">pharmaceutics16081092</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Foster C.S., Vitale A.T. Diagnosis &amp; Treatment of Uveitis; Jaypee Highlinghts. 2nd ed. Medical Publishers, Inc.; Philadelphia, PA, USA: 2002.</Citation></Reference><Reference><Citation>Kempen J.H., Gangaputra S., Daniel E., Levy-Clarke G.A., Nussenblatt R.B., Rosenbaum J.T., Suhler E.B., Thorne J.E., Foster C.S., Jabs D.A., et al. Long-Term Risk of Malignancy Among Patients Treated with Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence. Am. J. Ophthalmol. 2008;146:802–812. doi: 10.1016/j.ajo.2008.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2008.04.035</ArticleId><ArticleId IdType="pmc">PMC2614443</ArticleId><ArticleId IdType="pubmed">18579112</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber-Schöndorfer C. 2.12—Immunomodulators. In: Schaefer C., Peters P., Miller R.K., editors. Drugs During Pregnancy and Lactation. 2nd ed. Academic Press; Oxford, UK: 2007. pp. 321–334.</Citation></Reference><Reference><Citation>Yi J., Zhang Y., Liang R., Zhong F. Beta-Carotene Chemical Stability in Nanoemulsions Was Improved by Stabilized with Beta-Lactoglobulin—Catechin Conjugates through Free Radical Method. J. Agric. Food Chem. 2015;63:297–303. doi: 10.1021/jf5056024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf5056024</ArticleId><ArticleId IdType="pubmed">25514513</ArticleId></ArticleIdList></Reference><Reference><Citation>Major J., Foroncewicz B., Paweł J., Mucha K. Immunology and Donor- Specific Antibodies in Corneal Transplantation. Arch. Immunol. Ther. Exp. 2021;69:32. doi: 10.1007/s00005-021-00636-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-021-00636-3</ArticleId><ArticleId IdType="pmc">PMC8572187</ArticleId><ArticleId IdType="pubmed">34741683</ArticleId></ArticleIdList></Reference><Reference><Citation>Coster D.J., Williams K.A. The Impact of Corneal Allograft Rejection on the Long-Term Outcome of Corneal Transplantation. Am. J. Ophthalmol. 2005;140:1112–1122. doi: 10.1016/j.ajo.2005.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2005.07.024</ArticleId><ArticleId IdType="pubmed">16376660</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilbert E., Laroche L., Borderie V. Le Rejet d’allogreffe de Cornée. J. Fr. Ophtalmol. 2011;34:331–348. doi: 10.1016/j.jfo.2011.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfo.2011.02.001</ArticleId><ArticleId IdType="pubmed">21492957</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrós N., Mallandrich M., Beirampour N., Mohammadi R., Domènech Ò., Rodríguez-Lagunas M.J., Clares B., Colom H. Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome. Pharmaceutics. 2022;14:1895. doi: 10.3390/pharmaceutics14091895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14091895</ArticleId><ArticleId IdType="pmc">PMC9505846</ArticleId><ArticleId IdType="pubmed">36145642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko Y., Murakami T., Nishitsuka K., Takakubo Y. Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report. Front. Med. 2022;8:764067. doi: 10.3389/fmed.2021.764067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.764067</ArticleId><ArticleId IdType="pmc">PMC8795080</ArticleId><ArticleId IdType="pubmed">35096866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular Drug Delivery. Am. Assoc. Pharm. Sci. 2010;12:348–359. doi: 10.1208/s12248-010-9183-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-010-9183-3</ArticleId><ArticleId IdType="pmc">PMC2895432</ArticleId><ArticleId IdType="pubmed">20437123</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Chen L., Fu Y. Nanotechnology-Based Ocular Drug Delivery Systems: Recent Advances and Future Prospects. J. Nanobiotechnol. 2023;21:232. doi: 10.1186/s12951-023-01992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-023-01992-2</ArticleId><ArticleId IdType="pmc">PMC10362606</ArticleId><ArticleId IdType="pubmed">37480102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Yang J., Lu A., Gong J., Yang Y., Lin X., Li M., Xu H. Nanoparticles in Ocular Applications and Their Potential Toxicity. Front. Mol. Biosci. 2022;9:931759. doi: 10.3389/fmolb.2022.931759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.931759</ArticleId><ArticleId IdType="pmc">PMC9334523</ArticleId><ArticleId IdType="pubmed">35911959</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.Y., Tan K., Akbar D., Choulakian M.Y., Tran S.D. A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions. Pharmaceutics. 2023;15:1952. doi: 10.3390/pharmaceutics15071952.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15071952</ArticleId><ArticleId IdType="pmc">PMC10385446</ArticleId><ArticleId IdType="pubmed">37514137</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri R., Nag T.C., Mehra N., Neupane Y.R., Shafi S., Sharma D., Sharma K., Sultana Y., Kohli K. Sirolimus Loaded Chitosan Functionalized PLGA Nanoparticles Protect against Sodium Iodate-Induced Retinal Degeneration. J. Drug Deliv. Sci. Technol. 2023;82:104369. doi: 10.1016/j.jddst.2023.104369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2023.104369</ArticleId></ArticleIdList></Reference><Reference><Citation>Khiev D., Mohamed Z.A., Vichare R., Paulson R., Bhatia S., Mohapatra S., Lobo G.P., Valapala M., Kerur N., Passaglia C.L., et al. Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery. Nanomaterials. 2021;11:173. doi: 10.3390/nano11010173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano11010173</ArticleId><ArticleId IdType="pmc">PMC7828028</ArticleId><ArticleId IdType="pubmed">33445545</ArticleId></ArticleIdList></Reference><Reference><Citation>Janagam D.R., Wu L., Lowe T.L. Nanoparticles for Drug Delivery to the Anterior Segment of the Eye. Adv. Drug Deliv. Rev. 2017;122:31–64. doi: 10.1016/j.addr.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2017.04.001</ArticleId><ArticleId IdType="pmc">PMC6057481</ArticleId><ArticleId IdType="pubmed">28392306</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan J., Batrakova E., Gendelman H.E. Cell Delivery of Therapeutic Nanoparticles. 1st ed. Volume 104. Elsevier; Amsterdam, The Netherlands: 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016803</ArticleId><ArticleId IdType="pubmed">22093229</ArticleId></ArticleIdList></Reference><Reference><Citation>El Moussaoui S., Abo-horan I., Halbaut L., Alonso C., Coderch L., Garduño-ramírez M.L., Clares B., Soriano J.L., Calpena A.C., Fernández-campos F., et al. Polymeric Nanoparticles and Chitosan Gel Loading Ketorolac Tromethamine to Alleviate Pain Associated with Condyloma Acuminata during the Pre- and Post-ablation. Pharmaceutics. 2021;13:1784. doi: 10.3390/pharmaceutics13111784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13111784</ArticleId><ArticleId IdType="pmc">PMC8618351</ArticleId><ArticleId IdType="pubmed">34834198</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwer K., Muharram M.M., Mohammad M. Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin. Pharmaceutics. 2020;12:252. doi: 10.3390/pharmaceutics12030252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12030252</ArticleId><ArticleId IdType="pmc">PMC7151119</ArticleId><ArticleId IdType="pubmed">32168906</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade-Carrera B., Clares B., Noé V., Mallandrich M., Calpena A., García M., Garduño-Ramírez M. Cytotoxic Evaluation of (2S)-5,7-Dihydroxy-6-Prenylflavanone Derivatives Loaded PLGA Nanoparticles against MiaPaCa-2 Cells. Molecules. 2017;22:1553. doi: 10.3390/molecules22091553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22091553</ArticleId><ArticleId IdType="pmc">PMC6151514</ArticleId><ArticleId IdType="pubmed">28914822</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvajal-Vidal P., González-Pizarro R., Araya C., Espina M., Halbaut L., Gómez de Aranda I., García M.L., Calpena A.C. Nanostructured Lipid Carriers Loaded with Halobetasol Propionate for Topical Treatment of Inflammation: Development, Characterization, Biopharmaceutical Behavior and Therapeutic Efficacy of Gel Dosage Forms. Int. J. Pharm. 2020;585:119480. doi: 10.1016/j.ijpharm.2020.119480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119480</ArticleId><ArticleId IdType="pubmed">32479897</ArticleId></ArticleIdList></Reference><Reference><Citation>CPMP. ICH  . ICH Topic Q 1 A (R2) Stability Testing of New Drug Substances and Products. European Medicines Agency; London, UK: 2003.  [(accessed on 16 May 2022)].  Available online:  https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline.</Citation></Reference><Reference><Citation>Bruna T., Maldonado-Bravo F., Jara P., Caro N. Silver Nanoparticles and Their Antibacterial Applications. Int. J. Mol. Sci. 2021;22:7202. doi: 10.3390/ijms22137202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137202</ArticleId><ArticleId IdType="pmc">PMC8268496</ArticleId><ArticleId IdType="pubmed">34281254</ArticleId></ArticleIdList></Reference><Reference><Citation>Documento de La Real Farmacopea Española Por Internet. Eficacia de La Conservación Antimicrobiana.  [(accessed on 21 April 2022)].  Available online:  https://extranet.boe.es/farmacopea/doc.php?id=50103#.</Citation></Reference><Reference><Citation>Mohammadi-Meyabadi R., Beirampour N., Garrós N., Alvarado H.L., Limón D., Silva-Abreu M., Calpena A.C., Mallandrich M. Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies. Pharmaceutics. 2022;14:2714. doi: 10.3390/pharmaceutics14122714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14122714</ArticleId><ArticleId IdType="pmc">PMC9785369</ArticleId><ArticleId IdType="pubmed">36559208</ArticleId></ArticleIdList></Reference><Reference><Citation>ICCVAM-Recommended Test Method Protocol: Hen’s Egg Test—Chorioallantoic Membrane (HET-CAM) Test Method. NIH Publication; Bethesda, MD, USA: 2010.  [(accessed on 2 June 2022)].  Available online:  https://mdpi-res.com/data/mdpi_references_guide_v9.pdf.</Citation></Reference><Reference><Citation>Gopinathan U., Ramakrishna T., Willcox M., Rao C.M., Balasubramanian D., Kulkarni A., Vemuganti G.K., Rao G.N. Enzymatic, Clinical and Histologic Evaluation of Corneal Tissues in Experimental Fungal Keratitis in Rabbits. Exp. Eye Res. 2001;72:433–442. doi: 10.1006/exer.2000.0971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exer.2000.0971</ArticleId><ArticleId IdType="pubmed">11273671</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde Penedo A., Díaz Tomé V., Fernández Ferreiro A., González Barcia M., Otero Espinar F.J. Enhancement in Corneal Permeability of Riboflavin Using Cyclodextrin Derivates Complexes as a Previous Step to Transepithelial Cross-Linking. Eur. J. Pharm. Biopharm. 2021;162:12–22. doi: 10.1016/j.ejpb.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2021.02.012</ArticleId><ArticleId IdType="pubmed">33667681</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh M.I., Jadhav L.S., Jadhav R.K., Kadam J.V., Pisal S.S. Aceclofenac Organogels: In Vitro and In Vivo Characterization. Curr. Drug Deliv. 2009;6:1–7. doi: 10.2174/156720109787048320.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720109787048320</ArticleId><ArticleId IdType="pubmed">19418950</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-abreu M., Calpena A.C., Espina M., Silva A.M., Gimeno A., Egea M.A., García M.L. Optimization, Biopharmaceutical Profile and Therapeutic Eff Icacy of Pioglitazone-Loaded PLGA-PEG Nanospheres as a Novel Strategy for Ocular Inflammatory Disorders. Pharm. Res. 2018;35:11. doi: 10.1007/s11095-017-2319-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-017-2319-8</ArticleId><ArticleId IdType="pubmed">29299768</ArticleId></ArticleIdList></Reference><Reference><Citation>Laignier Cazedey E., Carvalho F.C., Másquio Fiorentino F.A., Daflon Gremiao M.P., Nunes Salgado H.R. Corrositex®, BCOP and HET-CAM as Alternative Methods to Animal Experimentation. Braz. J. Pharm. Sci. 2009;45:759–766. doi: 10.1590/S1984-82502009000400021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1984-82502009000400021</ArticleId></ArticleIdList></Reference><Reference><Citation>Danaei M., Dehghankhold M., Ataei S., Hasanzadeh Davarani F., Javanmard R., Dokhani A., Khorasani S., Mozafari M.R. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018;10:57. doi: 10.3390/pharmaceutics10020057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics10020057</ArticleId><ArticleId IdType="pmc">PMC6027495</ArticleId><ArticleId IdType="pubmed">29783687</ArticleId></ArticleIdList></Reference><Reference><Citation>Teweldemedhin M., Gebreyesus H., Atsbaha A.H., Asgedom S.W., Saravanan M. Bacterial Profile of Ocular Infections: A Systematic Review. BMC Ophthalmol. 2017;17:212. doi: 10.1186/s12886-017-0612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-017-0612-2</ArticleId><ArticleId IdType="pmc">PMC5702129</ArticleId><ArticleId IdType="pubmed">29178851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiacek A.E., Jurak M., Ładniak A., Szafran K., Przykaza K. Cyclosporine CsA—The Physicochemical Characterization of Liposomal and Colloidal Systems. Colloids Interfaces. 2020;4:46. doi: 10.3390/colloids4040046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/colloids4040046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheow W.S., Hadinoto K. Colloids and Surfaces B: Biointerfaces Factors Affecting Drug Encapsulation and Stability of Lipid—Polymer Hybrid Nanoparticles. Colloids Surf. B Biointerfaces. 2011;85:214–220. doi: 10.1016/j.colsurfb.2011.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2011.02.033</ArticleId><ArticleId IdType="pubmed">21439797</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigo-Gutierrez J.K., Vega-Chacón Y., Brandao A., Garcia de Oliverira-Mima E. Antimicrobial Activity of Curcumin in Nanoformulations: A Comprehensive Review. Int. J. Mol. Sci. 2021;22:7130. doi: 10.3390/ijms22137130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137130</ArticleId><ArticleId IdType="pmc">PMC8267827</ArticleId><ArticleId IdType="pubmed">34281181</ArticleId></ArticleIdList></Reference><Reference><Citation>Onugwu A.L., Nwagwu C.S., Onugwu O.S., Echezona A.C., Agbo C.P., Ihim S.A., Emeh P., Nnamani P.O., Attama A.A., Khutoryanskiy V.V. Nanotechnology Based Drug Delivery Systems for the Treatment of Anterior Segment Eye Diseases. J. Control. Release. 2023;354:465–488. doi: 10.1016/j.jconrel.2023.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.01.018</ArticleId><ArticleId IdType="pubmed">36642250</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Li S., Xu M., Zhong Y., Fan W., Xu J., Zhou T., Ji J., Ye J., Yao K. Polymer- and Lipid-Based Nanocarriers for Ocular Drug Delivery: Current Status and Future Perspectives. Adv. Drug Deliv. Rev. 2023;196:114770. doi: 10.1016/j.addr.2023.114770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2023.114770</ArticleId><ArticleId IdType="pubmed">36894134</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Suresh P.K. Drug Delivery to Eye: Special Reference to Nanoparticles. Int. J. Drug Deliv. 2010;2:12–21. doi: 10.5138/ijdd.2010.0975.0215.02007.</Citation><ArticleIdList><ArticleId IdType="doi">10.5138/ijdd.2010.0975.0215.02007</ArticleId></ArticleIdList></Reference><Reference><Citation>Razavi M.S., Ebrahimnejad P., Fatahi Y., D’Emanuele A., Dinarvand R. Recent Developments of Nanostructures for the Ocular Delivery of Natural Compounds. Front. Chem. 2022;10:850757. doi: 10.3389/fchem.2022.850757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.850757</ArticleId><ArticleId IdType="pmc">PMC9043530</ArticleId><ArticleId IdType="pubmed">35494641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahdar A., Sargazi S., Barani M., Shahraki S., Sabir F., Aboudzadeh M.A. Lignin-Stabilized Doxorubicin Microemulsions: Synthesis, Physical Characterization, and In Vitro Assessments. Polymers. 2021;13:641. doi: 10.3390/polym13040641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13040641</ArticleId><ArticleId IdType="pmc">PMC7926373</ArticleId><ArticleId IdType="pubmed">33670009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahdar A., Taboada P., Reza M., Barani M., Beyzaei H. Effect of Tocopherol on the Properties of Pluronic F127 Microemulsions: Physico-Chemical Characterization and in Vivo Toxicity. J. Mol. Liq. 2019;277:624–630. doi: 10.1016/j.molliq.2018.12.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2018.12.074</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvet A., Lacoulonche F., Egea M.A. PLGA Nanospheres for the Ocular Delivery of Flurbiprofen: Drug Release and Interactions. J. Pharm. Sci. 2008;97:5306–5317. doi: 10.1002/jps.21383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.21383</ArticleId><ArticleId IdType="pubmed">18425815</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrite A.C., Kompella U.B. Size-Dependent Disposition of Nanoparticles and Microparticles Following Subconjunctival Administration. J. Pharm. Pharmacol. 2005;57:1555–1563. doi: 10.1211/jpp.57.12.0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/jpp.57.12.0005</ArticleId><ArticleId IdType="pubmed">16354399</ArticleId></ArticleIdList></Reference><Reference><Citation>Samimi S., Maghsoudnia N., Eftekhari R.B., Dorkoosh F. Chapter 3—Lipid-Based Nanoparticles for Drug Delivery Systems. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery. Elsevier; Amsterdam, The Netherlands: 2019. pp. 47–76. Micro and Nano Technologies.</Citation></Reference><Reference><Citation>Gökçe E.H., Sandri G., Eğrilmez S., Bonferoni M.C., Güneri T., Caramella C. Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance and In Vivo Drug Release in Rabbit Eyes. Curr. Eye Res. 2016;34:996–1003. doi: 10.3109/02713680903261405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02713680903261405</ArticleId><ArticleId IdType="pubmed">19958116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.H., Khan F.N., Cosby L., Yang G., Winter J.O. Polymer Concentration Maximizes Encapsulation Efficiency in Electrohydrodynamic Mixing Nanoprecipitation. Front. Nanotechnol. 2021;3:719710. doi: 10.3389/fnano.2021.719710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnano.2021.719710</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshinoff S.A., Hofmann I., Nae H. Role of Rheology in Tears and Artificial Tears. J. Cataract Refract. Surg. 2021;47:655–661. doi: 10.1097/j.jcrs.0000000000000508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.jcrs.0000000000000508</ArticleId><ArticleId IdType="pubmed">33278231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia W., Qin N., Zhao P., Phan C.M., Haines L., Jones L., Ren C.L. Shear-Thinning and Temperature-Dependent Viscosity Relationships of Contemporary Ocular Lubricants. Transl. Vis. Sci. Technol. 2022;11:1. doi: 10.1167/tvst.11.3.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.11.3.1</ArticleId><ArticleId IdType="pmc">PMC8899858</ArticleId><ArticleId IdType="pubmed">35234832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiffany J.M. The Viscosity of Human Tears. Int. Ophthalmol. 1991;15:371–376. doi: 10.1007/BF00137947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00137947</ArticleId><ArticleId IdType="pubmed">1778667</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo A., Feng X., Patel D., Mohammad A., Kozak D., Choi S., Ashraf M., Xu X. Factors Affecting the Particle Size Distribution and Rheology of Brinzolamide Ophthalmic Suspensions. Int. J. Pharm. 2020;586:119495. doi: 10.1016/j.ijpharm.2020.119495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119495</ArticleId><ArticleId IdType="pubmed">32553495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa A., Gulmezian-Sefer M., Cheng Y., Srikumar R. Microbiological Considerations for Ophthalmic Products: Sterility, Endotoxin Limits, and Preservatives. In: Neervannan S., Kompella U.B., editors. Ophthalmic Product Development: From Bench to Bedside. Springer International Publishing; Cham, Switzerland: 2021. pp. 199–227.</Citation></Reference><Reference><Citation>Wilson C.G. Ophthalmic Formulation. In: Srivastava V., Pitt K., Tovey G.D., editors. Specialised Pharmaceutical Formulation: The Science and Technology of Dosage Forms. The Royal Society of Chemistry; Cambridge, UK: 2022.</Citation></Reference><Reference><Citation>Parra A., Mallandrich M., Clares B., Egea M.A., Espina M., García M.L., Calpena A.C. Design and Elaboration of Freeze-Dried PLGA Nanoparticles for the Transcorneal Permeation of Carprofen: Ocular Anti-Inflammatory Applications. Colloids Surf B Biointerfaces. 2015;136:935–943. doi: 10.1016/j.colsurfb.2015.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2015.10.026</ArticleId><ArticleId IdType="pubmed">26551871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirenkumar M., Steven S. Poly Lactic-Co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers. 2012;3:1377–1397. doi: 10.3390/polym3031377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym3031377</ArticleId><ArticleId IdType="pmc">PMC3347861</ArticleId><ArticleId IdType="pubmed">22577513</ArticleId></ArticleIdList></Reference><Reference><Citation>Diebold Y., Calonge M. Applications of Nanoparticles in Ophthalmology. Prog. Retin. Eye Res. 2010;29:596–609. doi: 10.1016/j.preteyeres.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2010.08.002</ArticleId><ArticleId IdType="pubmed">20826225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>